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Abstract
Background: Dysfunctions in the PI3K/mTOR pathway have gained a lot of attention in autism research. This was
initially based on the discovery of several monogenic autism spectrum disorders with mutations or defects in PI3K/
mTOR signaling components. Recent genetic studies corroborate that defective PI3K/mTOR signaling might be a
shared pathomechanism in autism disorders of so far unknown etiology, but functional molecular analyses in human
cells are rare. The goals of this study were to perform a functional screen of cell lines from patients with idiopathic
autism for defects in PI3K/mTOR signaling, to test if further functional analyses are suitable to detect underlying
molecular mechanisms, and to evaluate this approach as a biomarker tool to identify therapeutic targets.
Methods: We performed phospho-S6- and S6-specific ELISA experiments on 21 lymphoblastoid cell lines from
the AGRE collection and on 37 lymphoblastoid cell lines from the Simons Simplex Collection and their healthy
siblings. Cell lines from one individual with increased S6 phosphorylation and his multiplex family were analyzed
in further detail to identify upstream defects in PI3K signaling associated with autism diagnosis.
Results: We detected significantly increased S6 phosphorylation in 3 of the 21 lymphoblastoid cell lines from AGRE
compared to a healthy control and in 1 of the 37 lymphoblastoid cell lines from the Simons Simplex Collection
compared to the healthy sibling. Further analysis of cells from one individual with elevated S6 phosphorylation
showed increased expression of the PI3K catalytic subunit p110δ, which was also observed in lymphoblastoid
cells from other autistic siblings but not unaffected members in his multiplex family. The p110δ-selective inhibitor
IC87114 reduced elevated S6 phosphorylation and protein synthesis in this cell line.
Conclusions: Our results suggest that functional analysis of PI3K/mTOR signaling is a biomarker tool to identify
disease-associated molecular defects that could serve as therapeutic targets in autism. Using this approach, we
discovered impaired signaling and protein synthesis through the PI3K catalytic subunit p110δ as an underlying
molecular defect and potential treatment target in select autism spectrum disorders. Increased p110δ activity was
recently associated with schizophrenia, and our results suggest that p110δ may also be implicated in autism.
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Background
The PI3K/mTOR pathway regulates a variety of functions
throughout the body, including fundamental processes
such as cell growth, differentiation and survival. In neu-
rons, the PI3K/mTOR pathway was shown to regulate pro-
tein synthesis [1], to play a role in dendritic morphology
and axon outgrowth and regeneration [2–4], and to be im-
portant for synaptic plasticity [5–7]. Mutations in this
pathway are among the most abundant in cancer affecting
virtually all organs of the body including the nervous sys-
tem and particularly the brain. Several clinical trials have
been initiated to test PI3K/mTOR antagonists for their
efficacy to halt or reduce tumor growth [8], but more re-
cently this pathway has also gained considerable attention
for its dysregulation and potential applicability as a thera-
peutic target in other brain disorders, including epilepsy,
schizophrenia, and autism spectrum disorders [9–13].
Several monogenic autism spectrum disorders have
mutations leading to defects in the PI3K pathway, such
as tuberous sclerosis (TS) [14], fragile X syndrome (FXS)
[1, 15], neurofibromatosis 1 (NF1) [16], and brain disor-
ders associated with phosphatase and tensin homolog
(PTEN) mutations [17]. More recently, genome-wide as-
sociation studies and analyses of chromosome copy
number variations (CNVs) have revealed even more evi-
dence for dysregulation of the PI3K/mTOR signaling
complex in autism spectrum disorders [18–21]. Lastly,
autism has been associated with brain overgrowth, cortical
malformations, and aberrant growth trajectories [22], fur-
ther suggesting that dysfunctions in the PI3K/mTOR
pathway, an important regulator of cell growth, might
contribute to the autism etiology. However, to what extent
alterations in brain size and connectivity are a shared
characteristic of autism remains controversial [23].
Together, these findings suggest that there is a consid-
erable subgroup of autism spectrum disorders of un-
known etiology with defects in PI3K/mTOR signaling,
which could qualify for a therapeutic strategy targeted at
this pathway. While genetic screens are important to
identify potentially pathological mutations in the PI3K/
mTOR pathway, they do not directly reveal the func-
tional consequences and how signal transduction is
affected by a certain mutation in human patient cells.
Understanding the exact pathological mechanisms in
PI3K/mTOR signaling, which may be the sum of several
mutations as well as epigenetic factors, will be essential
to identify efficient, disease-targeting therapies.
Here, we tested the hypothesis that functional defects in
PI3K/mTOR signaling can be detected and utilized to
identify potential therapeutic targets in lymphoblastoid
cell lines from patients with idiopathic autism. In particu-
lar, we performed quantitative analyses of phosphorylation
of the PI3K/mTOR downstream target S6 in patient cell
lines from the Autism Genetic Research Exchange
(AGRE) collection and in proband-sibling pairs from the
Simons Simplex Collection (SSC). We identified several
cell lines with increased S6 phosphorylation suggesting el-
evated upstream signaling. We confirmed the pathological
relevance of increased S6 phosphorylation for one patient
from the AGRE collection by showing that his unaffected
sister did not have increased S6 phosphorylation. Analyses
of upstream signaling defects and pharmacological rescue
experiments using PI3K catalytic subunit-selective inhibi-
tors suggested that increased expression and activity of
the PI3K catalytic subunit p110δ, but not p110β, underlie
increased S6 phosphorylation and protein synthesis in this
autism patient cell line. This work supports the applicabil-
ity of functional molecular screens to detect signal trans-
duction defects in lymphoblastoid cell lines from patients
with autism that could serve as therapeutic targets.
Methods
Lymphoblastoid cell lines
Lymphoblastoid cell lines were obtained from the Autism
Genetic Research Exchange (AGRE; cell lines marked as
A1-A21, all male and diagnosed with autism, and A4-F,
-M, -S, -B1, -B2, -B3: multiplex family of A4, pedigree
shown in Fig. 5a), the Simons Simplex Collection (SSC,
cell lines marked as S1-37, including the individual with
autism (proband) and the unaffected sibling, all male), and
the Coriell Institute (Camden, NJ, USA; CTR, CTR-2).
The institutional review boards of Emory University and
Cincinnati Children’s Hospital Medical Center determined
that this research was “exempt” and no IRB approval was
required. Cell lines were grown in RPMI supplemented
with 10 % fetal bovine serum and penicillin/streptavidin
(100 U/ml) and kept at a cell density between 500,000 and
800,000 cells/ml. If cell lines differed in growth rates, as
monitored by change of color of the media and cell dens-
ity, they were discarded, and new batches were thawed.
Cell lines were only kept in culture and used for experi-
ments for up to 5 weeks. Experimental data were obtained
from at least two separate frozen vials of cell lines.
Antibodies and drugs
The phospho-S6 antibody (Ser235/236, #2211), S6 anti-
body (#2317), and p110α antibody (#4255) were obtained
from Cell Signaling Technology. p110δ antibodies (#sc-
7176, mab2687) were obtained from Santa Cruz Biotech-
nology and R&D Biosciences, respectively. The p110β
antibody (#09-482) was obtained from EMD Millipore,
the α-tubulin antibody (T6074) was obtained from
Sigma-Aldrich, and the anti-puromycin antibody was pur-
chased from the Developmental Studies Hybridoma Bank
(University of Iowa). Secondary antibodies for Western
blotting were obtained from VWR (horseradish peroxidase-
coupled anti-mouse and anti-rabbit antibodies for ECL) or
from Li-COR Biosciences (IRDye 680 RD donkey anti-
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mouse IgG and IRDye 800CW goat anti-rabbit IgG for
infrared fluorescent Western blotting). Puromycin was pur-
chased from Life Technologies, the p110δ inhibitor
IC87114 was purchased from EMD Millipore, and the
p110β inhibitor TGX-221 was purchased from Selleck
Chemicals.
S6- and phospho-S6 ELISAs
S6- and phospho-S6 ELISA kits were obtained from
Cell Signaling Technology and run in triplicates and in
parallel using 150 μg of protein per sample following
the manufacturer’s protocol. Lymphoblastoid cell lines
were lysed by sonication using the provided lysis buffer.
PI3K activity assay
PI3K activity assays were performed using the PI3-kinase
activity ELISA: Pico (Echelon Biosciences Incorporated) as
described previously [24]. Briefly, lymphoblastoid cell lines
were washed once with ice-cold PBS then lysed using
sonication in ice-cold PI3K assay lysis buffer (50 mM
Tris–HCl, pH 7.4, 40 mM NaCl, 1 mM EDTA, 0.5 % Tri-
ton X-100, 1.5 mM Na3VO4, 50 mM NaF, 10 mM sodium
pyrophosphate, and 10 mM sodium glycerol phosphate,
supplemented with proteinase inhibitors). One hundred
micrograms of protein was used for subsequent immuno-
precipitation with a p110δ-specific antibody (mab2687,
R&D Biosciences). PI3K assays were performed as de-
scribed by the manufacturer with the following modi-
fications: kinase reactions were conducted for 3 h in
60 μl volume; the reaction contained 75 μM ATP,
1 mM DTT, and 15 μM phosphatidylinositol (3,4)
biphosphate diC8 and was terminated with 2.4 mM
EDTA. The amount of phosphatidylinositol-(3,4,5)-tri-
phosphate generated during the reaction was quanti-
fied using defined standards.
Western blotting
Equal amounts of protein lysates (prepared as described
above) were resolved on SDS protein acrylamide gels,
transferred to PVDF membranes, and detected with spe-
cific antibodies by enhanced chemiluminescence using
standard methods and autoradiography (phospho-S6, S6,
p110α, p110β, p110δ, Akt, tubulin) or by Odyssey infrared
fluorescence Western blotting (Li-COR Biosciences) using
the manufacturer’s blocking buffer (PBS) for blocking and
antibody incubation (puromycin, Akt).
Protein synthesis assay
Protein synthesis assays were performed using puromyci-
nylation of nascent peptide chains as described previously
[25, 26]. Briefly, equal amounts of cells (ca. 4–7 million)
were resuspended in 7–8 ml of culturing media. Cells
were treated with 1 nM IC87114, 1 μM TGX-221, or an
equal amount of vehicle for 15 min, followed by
incubation with 0.5 μg/ml puromycin for another
15 min. Cells were spun down and washed three times
with ice-cold PBS and then lysed and analyzed by
puromycin-specific Western blotting as described above.
For quantification, signal intensities of the whole lanes
spanning the entire molecular weight range of proteins
were analyzed using ImageJ (NIH).
Statistics
Statistical analyses were performed using SAS® version 9.3
(SAS Institute Inc., Cary, NC; Fig. 2 and Additional file 1:
Figure S1d) and GraphPad Prism 6 (GraphPad Software
Incorporated; all other figures). Phospho-S6 and S6
levels in AGRE cells were analyzed by one-way ANOVA
followed by Dunnett’s post hoc analyses to compare
each autistic individual to the healthy control. SSC cells
were analyzed using a two-way ANOVA with family
and disease status as fixed factors. Pairwise compari-
sons (proband to his healthy sibling) were controlled
for type I errors by false discovery rate correction using
an overall error rate equal to 0.05. All other data were an-
alyzed by paired t tests, one-way ANOVA, or two-way
ANOVA as appropriate followed by post hoc analyses
(indicated in the text and figure legends). Bar dia-
grams and error bars illustrate means and standard
error of the mean; n is indicated in each figure and/
or figure legend.
Results
Identification of increased S6 phosphorylation in
lymphoblastoid cell lines from individuals with autism
Dysregulated PI3K/mTOR signaling in the brain has been
detected and successfully targeted to correct phenotypes
in several mouse models of autism, including FXS [1, 27–
31]. Defects in this signaling pathway might thus be a
shared, targetable pathological mechanism in autism dis-
orders of diverse etiologies. We and others have previously
shown that altered PI3K/mTOR signaling, which contrib-
utes to neuronal dysfunction and autistic-like phenotypes,
can be detected in peripheral cells from individuals with
FXS, such as lymphoblastoid cell lines and fibroblasts [24,
32, 33]. To assess if abnormal PI3K/mTOR-mediated sig-
naling as a shared molecular defect in autism is detectable
in peripheral cell lines from humans with idiopathic aut-
ism, we analyzed lymphoblastoid cell lines from the Aut-
ism Genetic Research Exchange (AGRE) collection and
the Simons Simplex Collection (SSCs). AGRE collects
lymphocytes from autistic individuals from simplex and
multiplex families with none, one, or several additional
siblings diagnosed with autism, whereas the SSC contains
lymphoblastoid cell lines from families with one autistic
child that has at least one healthy sibling. S6 phosphoryl-
ation and S6 expression from 21 individuals with autism
from AGRE were compared to an unaffected control using
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ELISA analyses (Fig. 1). Three out of 21 individuals
showed significantly increased S6 phosphorylation com-
pared to an unaffected control (Fig. 1a, one-way ANOVA
F(21,85) = 3.5; p < 0.0001, Dunnett’s post hoc comparisons
of autism cell lines to the unaffected control *p < 0.05).
Two of these three also had significantly increased S6
expression, suggesting that increased phosphorylation
was due to an overall increase in S6 (Fig. 1b, one-way
ANOVA F(21,85) = 5.47; p < 0.0001, Dunnett’s post hoc
comparisons of all autism cell lines to the unaffected
control *p < 0.05). No differences in total S6 levels
between any other cell line and the control cell line
were detected. Consequently, one cell line (A4) had sig-
nificantly increased pS6/S6 ratios suggesting a defect in
the upstream signaling pathway (Fig. 1c, one-way ANOVA
F(21,85) = 2.34; p = 0.003, Dunnett’s post hoc comparisons
of all autism cell lines to the unaffected control *p =
0.013). A list of p values for all pairwise comparisons can
be found in Additional file 2: Table S1a. Independent re-
peats of assays in the unaffected control used in Fig. 1 as
well as experiments using an additional unaffected control
line (CTR-2) supported the reproducibility of the assay
Fig. 1 Phospho-S6- and S6-specific ELISAs on lymphoblastoid cell lines from patients with idiopathic autism from AGRE. a Phosphorylation of S6
is significantly increased in three cell lines (A1, A4, and A5) (one-way ANOVA F(21,85) = 3.5; p < 0.0001, Dunnett’s post hoc comparisons of autism
cell lines to the unaffected control (CTR) *p(A1) = 0.041, *p(A4) = 0.011, *p(A5) = 0.015). b Expression of total S6 (phosphorylated and unphosphorylated)
shows much less variability than phospho-S6. Two of the three cell lines with increased S6 phosphorylation also have increased S6 levels
(A1 and A5) (one-way ANOVA F(21,85) = 5.468; p < 0.0001, Dunnett’s post hoc comparisons of autism cell lines to the unaffected control
*p(A1) = 0.013, *p(A5) = 0.0003). c Phospho-S6/S6 ratios were significantly increased in cell line A4, suggesting an upstream signal transduction
defect (one-way ANOVA F(21,85) = 2.34; p = 0.003, Dunnett’s post hoc comparisons of autism cell lines to the unaffected control *p(A4) = 0.014). N = 4,
shown are means + SEM. List of p values for all pairwise comparisons in Additional file 2: Table S1a. Further control experiments are shown in
Additional file 1: Figure S1a–c
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results and showed that there was no significant difference
in S6 phosphorylation in the two control lines (Additional
file 1: Figure S1a–c). Nonetheless, differences in S6 phos-
phorylation could be due to autism-unrelated inherited
genetic predispositions, and a lymphoblastoid cell line
generated from a random, unrelated healthy individual
might thus not be the ideal control. To address this issue,
we followed a second approach, in which we took advan-
tage of the SSC, a collection of lymphoblastoid cell lines
from autism simplex families, in which for every individ-
ual with autism, at least one healthy sibling is available.
Here, we directly compared every cell line from af-
fected individuals with the cell line from the respect-
ive unaffected sibling. In 2 out of 37 proband-sibling
pairs (S1 and S11), there was a consistent increase in
the ratio of phospho-S6 to S6 in the proband com-
pared to his healthy sibling in four repeats, with p <
0.05 for one pair (S1) after false discovery rate correc-
tion (Fig. 2, two-way-ANOVA, family and disease
status as fixed factors; list of p values for all pairwise
comparisons in Additional file 2: Table S1b). To further
investigate whether differences in S6 phosphorylation
could be due to autism-independent genetic predisposi-
tions in unrelated individuals, we compared phospho-
S6/S6 ratios in the unaffected siblings. A one-way
ANOVA showed a significant difference (F(36,109) =
1.7, p = 0.018), which was mainly driven by sibling S37
(see Additional file 1: Figure S1d, and associated figure
legend). Of note, this was an effect of the family S37, as
the phospho-S6/S6 ratio of the proband S37 was very
low, too, and there was no difference between sibling
S37 and the proband S37 (FDR-adjusted p = 0.919; Fig. 2
and Additional file 2: Table S1b). These results show
that most unaffected controls have similar phospho-
S6/S6 ratios (CTR and CTR-2, healthy siblings S1-S36).
This data further supports the validity of our approach
to directly compare autistic individuals to their healthy
family members to account for effects of autism-
unrelated genetic predispositions or environmental
influences.
Elevated expression and activity of the PI3K catalytic
subunit p110δ in a cell line with increased S6
phosphorylation
We next assessed whether lymphoblastoid cell lines pro-
vide a suitable tool to identify molecular mechanisms
leading to increased cell signaling. First, we performed
Western blot analyses and confirmed that, similar as ob-
served in the ELISA assays, S6 phosphorylation of cell
line A4 (AGRE) was increased compared to cell line A21
and the unaffected control (Fig. 3a, b, one-way ANOVA
F(2,9) = 35.36, p < 0.0001; Tukey’s post hoc analyses
*p = 0.0004; #p < 0.0001). We have previously shown
that increased expression of the PI3K catalytic subunit
p110β contributes to increased S6 phosphorylation in
lymphoblastoid cell lines from patients with FXS [24]. We
thus hypothesized that increased phospho-S6/S6 ratios in
patient cell line A4 may be caused by increased expression
and activity of a PI3K catalytic subunit. In contrast to
FXS, the PI3K catalytic subunit p110β was not changed
(Fig. 3a, c, one-way ANOVA F(2,9) = 0.66, p = 0.54). How-
ever, Western blot analyses revealed that cell line A4 had
increased expression of the class I PI3K subunit p110δ
compared to cell line A21 and the unaffected control
(Fig. 3a, d, one-way ANOVA F(2,9) = 10.42, p = 0.0045;
Tukey’s post hoc analyses *p = 0.0144; #p = 0.0056). In line
with the increased expression of p110δ, p110δ-associated
PI3K activity was also elevated in cell line A4 compared to
cell line A21 and the unaffected control (Fig. 3e, one-way
ANOVA F(2,21) = 14.73, p = 0.0001; Tukey’s post hoc ana-
lyses *p = 0.0002, #p = 0.0006). We further tested if similar
defects were detectable in cell lines S1 and S11 (SSC; see
Fig. 2). Western blot analyses showed increased S6 phos-
phorylation in S1 and S11 but not in S3 (Fig. 4, paired
t tests, (a) n = 3, t(2) = 10.7, p = 0.009; (b) n = 4, t(3) =
10.39, p = 0.002; (c) n = 4, t(3) = 0.72, p = 0.525), thereby
confirming our ELISA results (Fig. 2). In contrast to
cell line A4, neither S1 nor S11 showed consistent and
significant differences in the expression of the class IA
PI3K subunits p110α, p110β, or p110δ (Additional file 3:
Figure S2), suggesting that other upstream or downstream
Fig. 2 Phospho-S6/S6 ratios of lymphoblastoid cells from autistic individuals and their unaffected sibling from the SSC. ELISA analyses showed
that one autistic individual had a significantly increased phospho-S6/S6 ratio compared to his healthy sibling (two-way ANOVA, family and disease
status as fixed factors, disease status F(1,218) = 0.07, p = 0.79; family F(36,218) = 3.02, p < 0.0001; interaction F(36,218) = 1.24, p = 0.17; false discovery
rate-corrected *p = 0.003). N = 3–4, shown are means + SEM. List of p values for all pairwise comparisons in Additional file 2: Table S1b. Further
control experiments are described in Additional file 1: Figure S1d.
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defects in the PI3K/mTOR pathway may cause altered S6
phosphorylation. Alternatively, mutations within PI3K
catalytic subunits may change their activity but not ex-
pression and lead to increased S6 phosphorylation.
Increased p110δ expression may be associated with
autism diagnosis in a multiplex family
We next took advantage of the fact that the AGRE col-
lection stores lymphoblastoid cell lines and data from
entire multiplex families. Cell line A4 was derived from
an individual that has two unaffected parents (A4-F, A4-
M), one unaffected sister (A4-S), and three brothers with
autism (A4-B1, A4-B2, A4-B3), one of which is his twin
brother (A4-B1) (Fig. 5a). Western blot analyses of the
parents, the sister, and two brothers showed significant
differences in p110δ expression among family members
(Fig. 5b, one-way ANOVA, F(5,30) = 3.14, p = 0.021).
Post hoc analyses comparing all family members to the
healthy sister suggested that p110δ expression in the
three affected sons was increased compared to the
Fig. 3 Elevated expression and activity of the PI3K catalytic subunit p110δ in an autism cell line with increased pS6/S6 ratio. a Example Western
blots showing increased phosphorylation of S6, increased p110δ, but no changes in S6, p110β, or tubulin in cell line A4 compared to another
autism cell line (A21) and an unaffected control (CTR). b–d Densitometric quantification of pS6- (b), p110β- (c), and p110δ- (d) specific Western
blots shows significantly increased S6 phosphorylation and p110δ levels but no changes in p110β (n = 4, one-way ANOVAs with Tukey’s post hoc
analyses; b F(2,9) = 35.36; p < 0.0001; *p = 0.0004, #p < 0.0001; c F(2,9) = 0.66; p = 0.54; d F(2,9) = 10.42; p = 0.0045; *p = 0.014, #p = 0.0056). All values
were normalized to tubulin. e p110δ-associated PI3K activity is significantly increased in cell line A4 compared to cell line A21 and the unaffected
control (n = 8, one-way ANOVA with Tukey’s post hoc analyses, F(2,21) = 14.73; p = 0.0001; *p = 0.0002, #p = 0.0006). Bar diagrams are means + SEM
Fig. 4 Western blot analyses confirm increased S6 phosphorylation in select SSC cell lines compared to their unaffected siblings. S6 phosphorylation
was significantly increased in cell line S1 (a, n = 3, paired t test, t(2) = 10.7, p = 0.009) and S11 (b, n = 4, paired t test, t(3) = 10.39, p = 0.002) but
not in S3 (c, n = 4, paired t test, t(3) = 0.72, p = 0.525), confirming ELISA results shown in Fig. 2. Example Western blots are shown on the
top and densitometric quantification of three to four independent experiments below. Phosphorylated S6 was normalized to tubulin. Bar
diagrams are means + SEM. None of the class IA PI3K catalytic subunits p110α, p110β, or p110δ was significantly different in S1 or S11 compared to
their unaffected siblings (see Additional file 3: Figure S2)
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unaffected parents and sister, although statistical signifi-
cance was not reached (p values for post hoc comparison
to the unaffected sister shown in Additional file 4: Table
S2a). Similarly, phospho-S6- and S6-specific ELISA ana-
lyses showed that phospho-S6/S6 ratios are significantly
different among family members, and post hoc analyses
suggested that phospho-S6/S6 ratios may be increased in
the three family members with autism (Fig. 5c, one-way
ANOVA, F(5,24) = 3.77, p = 0.012; p values for post hoc
comparisons to the unaffected sister shown in Additional
file 4: Table S2b). To further assess if increased p110δ
expression and increased phosphorylation of S6 are asso-
ciated with autism in this specific multiplex family, we
compared pooled data from the autistic family members
with those from unaffected family members. Analysis of
pooled expression data from the three unaffected and
the three affected lymphoblastoid cell lines showed that
overall p110δ expression and S6 phosphorylation were
significantly increased in lymphoblastoid cells from
individuals with autism compared to unaffected indi-
viduals in this specific family (Fig. 5d, e, paired t tests,
(d) t(5) = 4.99, p = 0.004; (e) t(4) = 4.81, p = 0.009). How-
ever, we cannot exclude that the difference observed in
the pooled data, in particular in pS6/S6 ratios, was
mainly driven by cell line A-4, which was originally
identified in our screen. The cell line of one of the af-
fected brothers (A4-B3) did not grow well and therefore
was excluded from the analysis.
Elevated S6 phosphorylation and protein synthesis rates in
cell line A4 are reduced with a p110δ-selective inhibitor
Increased PI3K activity and S6 phosphorylation con-
tribute to increased protein synthesis in FXS mouse
models and cell lines from individuals with FXS [1, 24,
26–28, 33]. To assess whether elevated p110δ expres-
sion and activity in cell line A4 likewise leads to in-
creased basal protein synthesis, we quantified protein
synthesis rates in cell line A4 and the unaffected sister
cell line A4-S using puromycin-labeling and anti-
puromycin-specific Western blotting [25]. We detected
increased protein synthesis rates in cell line A4, which
were reduced to control levels by the p110δ-selective
inhibitor IC87114 [34] (Fig. 6a, two-way ANOVA Finter-
action(1,6) = 10.73, pinteraction = 0.017; Ftreatment(1,6) =
9.34, ptreatment = 0.022; Fautism(1,6) = 1.20, pautism = 0.316;
Sidak’s post hoc analyses *p = 0.010, #p = 0.011). Protein
synthesis rates in the cell line from the unaffected sib-
ling were not affected by the p110δ inhibitor (p =
Fig. 5 Increased p110δ expression and S6 phosphorylation is associated with autism in an autism multiplex family. a Pedigree of the multiplex family
of patient A4. Black indicates autism diagnosis, and black and white indicates “not quite autism” (modified from the AGRE catalogue). b p110δ-specific
Western blot analysis of the parents and three siblings of A4; example Western blot is shown on the left and quantification on the right.
One-way ANOVA analysis shows a significant difference (n = 6, F(5,30) = 3.14, p = 0.021; p values of post hoc analyses comparing all family
members to the healthy sibling shown in Additional file 4: Table S2a). c Similarly, phospho-S6-specific ELISAs suggested increased S6 phosphorylation
in the autistic family members (n = 5, one-way ANOVA, F(5,24) = 3.77, p = 0.012; p values of post hoc analyses comparing all family members to
the healthy sibling shown in Additional file 4: Table S2b). d Combining p110δ expression data from unaffected (A4-F, A4-M, A4-S) and autistic
(A4, A4-B1, A4-B2) family members shows a significant increase in p110δ expression in the family members diagnosed with autism compared
to their unaffected relatives (paired t test, n = 6, t(5) = 4.99, p = 0.004). e Combining phospho-S6 data from unaffected and autistic family members,
respectively, again shows significantly increased S6 phosphorylation in cell lines from family members with autism (n = 5, paired t test,
t(4) = 4.81, p = 0.009). Shown are means + SEM
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0.907). The specificity of the effect of the p110δ-
inhibitor on protein synthesis rates was further con-
firmed by experiments showing that a selective inhibitor
of the PI3K catalytic subunit p110β, TGX-221, did not
significantly affect protein synthesis in cell line A4 (Fig. 6b,
n = 4, paired t test, t(3) = 0.34, p = 0.76). In contrast, the
p110δ-selective inhibitor reduced S6 phosphorylation
in both cell lines, suggesting that additional p110δ-
dependent mechanisms, apart from increased S6 phos-
phorylation, lead to increased protein synthesis rates in
the cell line A4 (Fig. 6c, two-way ANOVA with Sidak’s
post hoc tests Fautism(1,3) = 35.01, pinteraction = 0.001; Ftreat-
ment(1,3) = 163.2, ptreatment = 0.001; Fautism(1,3) = 4.15, paut-
ism = 0.135; *p = 0.003,
#p = 0.0005; $p = 0.0019). Of note,
the p110β-selective inhibitor also reduced S6 phosphoryl-
ation in cell line A4 (Fig. 6d, n = 5, paired t test, t(4) =
5.75, p = 0.005), similarly as we have observed previously
in lymphoblastoid cell lines from a patient with FXS and a
healthy control [24].
Discussion
The development of disease-modifying therapies for aut-
ism spectrum disorders is hindered by the variety of
contributing factors and the limited knowledge about
the underlying pathological mechanisms. Easily assess-
able biomarkers that offer insight into defective molecu-
lar pathways in individual patients provide a potential
avenue for the design of targeted, personalized thera-
peutic strategies and could help to stratify patients into
sub-cohorts that would benefit from certain treatments.
Ideally, these biomarkers should provide quantitative
measurements that can also be used to evaluate the effi-
ciency of treatment strategies. Here, we provide initial evi-
dence that quantitative screens for signaling defects in
peripheral cell lines from individuals with autism could
fulfill these criteria for a biomarker and are suitable to de-
tect molecular pathological mechanisms that may serve as
therapeutic targets. Apart from this conceptual advance,
our results also corroborate previous studies suggesting
Fig. 6 Increased S6 phosphorylation and protein synthesis in the patient cell line are decreased with a p110δ-selective inhibitor. a Protein synthesis
assays using metabolic labeling of nascent peptide chains with puromycin followed by puromycin-specific Western blots show that basal protein
synthesis rates in the cell line from the autistic patient (A4) are increased compared to cell lines from his unaffected sibling (A4-S). The
p110δ-selective inhibitor IC87114 (1 nM, 15 min) reduces protein synthesis rates in the autistic patient but does not affect protein synthesis in
the unaffected sibling (n = 7, two-way ANOVA Finteraction(1,6) = 10.73, pinteraction = 0.017; Ftreatment(1,6) = 9.34, ptreatment = 0.022; Fautism(1,6) = 1.20, pautism =
0.316; Sidak’s post hoc analyses *p = 0.010, #p = 0.011). Example Western blot is shown on the right; “no puro” samples show background staining
without puromycin treatment of the cells. b In contrast, the p110β-selective inhibitor TGX-221 (1 μM, 15 min) does not affect protein synthesis
rates in cell line A4 (n = 4, paired t test, t(3) = 0.34, p = 0.76). Example Western blot is shown on the right; samples were loaded in duplicates. c Selective
inhibition of p110δ with IC87114 decreases S6 phosphorylation in the cell lines from both the autistic individual and his unaffected sister.
Quantification of ELISAs is shown on the left (n = 4, two-way ANOVA with Sidak’s post hoc tests Fautism(1,3) = 35.01, pinteraction = 0.001; Ftreatment(1,3) =
163.2, ptreatment = 0.001; Fautism(1,3) = 4.15, pautism = 0.135; *p = 0.003,
#p = 0.0005; $p = 0.0019). Example Western blot is shown on the right. d Similarly,
selective inhibition of p110δ with TGX-221 reduces S6 phosphorylation in cell line A4 as measured by Western blotting (n = 5, paired t test, t(4) = 5.75,
p = 0.005). Representative Western blot is shown on the right; samples were loaded in duplicates. Shown are means + SEM
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that dysregulated PI3K/mTOR signaling is a common
pathological mechanism shared by a sub-cohort of autism
spectrum disorders with unknown etiology.
Functional screens in peripheral blood cell lines are
suitable to detect signaling defects in idiopathic autism
We used lymphoblastoid cell lines from patients with
autism of unknown etiology obtained from the AGRE
collection and the SSC to test the hypothesis that dys-
regulated PI3K/mTOR signaling is a shared patho-
logical mechanism, treatment target, and biomarker in
autism. This hypothesis is based on previous studies
that found gene mutations in the PI3K/mTOR pathway
in monogenic and idiopathic forms of autism [9, 12, 20].
Instead of screening for genetic defects, we took a
functional approach that tested the activation of the
PI3K/mTOR downstream target S6 in patient cells.
This strategy has the advantage that molecular defects
caused by a variety of factors, including genetic, epigen-
etic, and environmental influences, can be detected. In
this pilot study, we screened lymphoblastoid cell lines
from 58 individuals with autism and detected signifi-
cantly increased S6 phosphorylation in 4 cell lines com-
pared to a healthy control (AGRE cell lines) or their
healthy siblings (SSC cell lines). This confirms previous
genetic studies suggesting that defects in the PI3K/
mTOR pathway may be a shared pathomechanism in a
sub-cohort of individuals with autism [20], in addition
to the known syndromic cases associated with altered
PI3K/mTOR signaling (such as FXS, TS, and NF-1).
Based on current published data, it is difficult to esti-
mate what the prevalence of autism with PI3K/mTOR
signaling defects is. Further complicating is the fact that
it is unknown which of the observed autism-associated
mutations within this pathway indeed lead to a func-
tional defect and are thus truly disease-causing. To ob-
tain a more accurate estimate of the percentage of
autism spectrum disorders that have a PI3K/mTOR sig-
naling defect detectable in peripheral cells, it will be
essential to perform large-scale screens analyzing hun-
dreds or thousands of individuals with autism. There
are currently cell lines from ~2500 autistic patients and
their siblings in the SSC, and ca. 1000 multiplex and
simplex families in the AGRE collection, which could
be analyzed in these functional screens in the future.
Due to the relatively high variability of PI3K/mTOR
signaling, we expect that only consistent and pro-
nounced changes will be detectable, and some more
moderate defects that might be disease-causing could
be missed. In the future, it will be important to com-
bine functional screens with genetic analyses to provide
the highest sensitivity to detect alterations in the PI3K/
mTOR pathway.
Dysregulated signaling through p110δ in autism and
schizophrenia suggests an important role in neuronal
function
PI3K catalytic subunits exist in eight isoforms, which are
categorized into class I, class II, and class III depending on
their structure and function [35]. The four class I PI3K
catalytic isoforms, p110α, p110β, p110γ, and p110δ, were
shown to play distinct and unique roles in non-neuronal
cells [36]. More recently, evidence is increasing that class I
PI3K isoforms also have diverse functions in the brain
and are dysregulated in neurological diseases [11]. For
example, increased p110β expression was detected in
the intellectual disability fragile X syndrome [1, 15, 24],
and defects in p110δ expression and activity have been as-
sociated with schizophrenia [10]. In the present study, we
show that p110δ is increased in several autistic siblings
but not the unaffected sister of a multiplex family. This
finding suggests that, apart from schizophrenia, altered
p110δ is also implicated in the etiology of autism. We did
not detect increased p110δ expression in two unrelated
cell lines from autistic individuals with increased S6 phos-
phorylation, suggesting other upstream signaling defects.
Future large-scale studies are needed to assess the preva-
lence of p110δ dysregulation in autism. However, even if
the frequency is low, we believe that its usability as an
easily detectable biomarker combined with the availability
of PI3K subunit-selective drugs makes p110δ an attractive
potential treatment target in autism.
So far, little is known about the molecular mechanisms
regulated by p110δ in neurons. A previous study has
shown that p110δ is important for axon outgrowth and
regeneration [2], but the exact signaling pathways are
unknown. Our study provides further insight into the
signaling pathways regulated by p110δ by showing that
increased p110δ expression in lymphoblastoid cells from
an individual with autism leads to elevated S6 phosphor-
ylation and increased protein synthesis rates, which can
be reversed by a p110δ-selective inhibitor. Interestingly,
while the p110δ-selective inhibitor reduced S6 phos-
phorylation in the cells from the autistic individual and
his unaffected sister, it reduced protein synthesis rates
only in cells from the autistic individual but not the un-
affected sister. Notably, these results resemble our previ-
ous study, in which we made a very similar observation
using a p110β-selective inhibitor in lymphoblastoid cell
lines from an individual with fragile X syndrome [24].
Cells from individuals with FXS have increased p110β
expression due to loss of translational control of the
p110β messenger RNA (mRNA) [1, 24, 33]. A p110β-
selective inhibitor reduced S6 phosphorylation in a cell
line from an individual with FXS and in an unaffected
control line, whereas protein synthesis rates were only
reduced in cells from a patient with FXS but not altered
by the inhibitor in control cells [24]. We speculate that
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both p110δ and p110β regulate S6 phosphorylation in
lymphoblastoid cells, leading to reduced S6 phosphor-
ylation when inhibited. In contrast, p110β- or p110δ-
mediated protein synthesis may be a gain of function
due to the increased p110β or p110δ levels in the
FXS cells or in cell line A4, respectively. In line with
this hypothesis, a selective p110β inhibitor reduced S6
phosphorylation in cell line A4 but did not affect pro-
tein synthesis, further supporting the specificity of the
underlying defect in p110δ expression and activity in
cell line A4.
Dysregulated mRNA translation was observed in several
autism spectrum disorders [37], supporting the hypothesis
that defects in p110δ-mediated protein synthesis may
contribute to the autistic phenotype in this family and
possibly others. We have recently shown that increased
activity of p110β contributes to dysregulated protein syn-
thesis downstream of group 1 metabotropic glutamate
receptors in a mouse model of fragile X syndrome [28]. A
previous study suggests that p110δ is signaling down-
stream of ErbB4 [10], but so far it is unknown if p110δ
controls protein synthesis mediated by ErbB4 or other
neurotransmitter receptors.
The fact that p110δ, which is dysregulated in schizo-
phrenia, may be altered in autism further supports the
hypothesis that autism spectrum disorders and schizo-
phrenia share common neurobiology and contributing
pathological mechanisms [38]. In non-neuronal cells,
p110δ plays an important role in mediating inflamma-
tory processes, and recently, p110δ has been proposed
as a potential treatment target to reduce stroke-induced
neuroinflammation in the brain [39]. Notably, both
schizophrenia and autism spectrum disorders have
been linked to increased neuroinflammation in the
brain [40, 41]. In the future, it will be interesting to
analyze the role of dysregulated p110δ activity in al-
tered neuroinflammation in these diseases.
Detecting functional molecular defects to identify
therapeutic targets
A large number of studies have identified gene muta-
tions or chromosomal CNVs that are associated with an
increased risk to develop autism [42]. These studies have
helped tremendously to shape our understanding of the
diverse etiology of autism [43]. However, recent studies
suggest a 50–60 % heritability of autism [44, 45], indicat-
ing that other factors in addition to gene mutations,
such as the environment or epigenetics, play important
roles in the development of autism. Most likely, autism
and the contributing alterations on the molecular level
arise from a combination of one or multiple gene muta-
tions plus epigenetic factors and environmental influ-
ences. Here, we detected a functional defect; increased
S6 phosphorylation caused by elevated expression of the
PI3K subunit p110δ in autistic but not unaffected mem-
bers of a multiplex autism family. Analyses of the avail-
able genetic data (AGRE) revealed no CNV affecting the
PIK3CD gene (located on chromosome 1p36.2) in these
families. Forthcoming studies will have to show if other
genetic factors contribute to the observed signaling
defects, for example, through targeted sequencing of
candidate genes. In this study, we have found increased
protein expression of p110δ. So far, the factors and sig-
naling pathways influencing p110δ expression are mostly
unknown [46, 47]. In the future, it will be interesting to
reveal mechanisms regulating p110δ expression and to
investigate if they are mutated in the multiplex family
studied here. Analyzing the functional outcome of
molecular defects in addition to genomic studies may
help to advance the application of precision medicine to
develop therapeutic treatments in individuals with aut-
ism. Functional studies also have the advantage to detect
a molecular defect regardless of the contributing genetic,
epigenetic, or environmental factors. This could facilitate
the development of treatments targeted at a disease-
causing defect without exact knowledge of the under-
lying cause.
Conclusions
Using lymphoblastoid cell lines from patients with idio-
pathic autism, we confirm that defects in S6 phosphor-
ylation occur in autism spectrum disorders of unknown
etiology. For one case, we show that this defect is
caused by alterations in PI3K/mTOR signaling, in par-
ticular the catalytic subunit p110δ. It is noteworthy that
S6 phosphorylation is regulated by other signaling path-
ways, in addition to PI3K/mTOR, for example, the
ERK1/2 pathway. The approach described here could
thus detect alterations in several upstream signaling
pathways, not only the PI3K/mTOR complex. Limita-
tions of the analysis of lymphoblastoid cell lines are (1)
that the process generating lymphoblastoid cell lines by
Epstein-Barr virus-mediated transformation of blood
lymphocytes may itself lead to alterations in signaling
and (2) that defects that are restricted to neurons will
not be detected. Artifacts in PI3K signaling that are due
to the transformation of lymphocytes into lymphoblas-
toid cell lines could be avoided by directly analyzing
lymphocytes purified from peripheral blood samples of
patients. However, using fresh blood samples would
make larger screens less feasible. Notably, our Western
blot analyses suggest that p110δ expression is increased
in lymphoblastoid cell lines from several autistic broth-
ers within one family but not in lymphoblastoid cell
lines from the unaffected sister or parents. These re-
sults suggest that the altered PI3K signaling is due to a
genetic predisposition within this family and not an
artifact caused by the process of lymphoblastoid cell
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generation. In the future, results generated with lym-
phoblastoid cells from patients should be confirmed in
lymphocytes from peripheral blood samples. Analyzing
lymphoblastoid cell lines is not suited to detect signal-
ing defects that are restricted to neuronal cells; how-
ever, the feasibility of the method and the availability of
large collections of lymphoblastoid cell lines from indi-
viduals with autism and their families justify this
approach. In addition, previous studies in FXS have
shown that brain defects detected in mouse models are
also present in human peripheral cells, such as blood
lymphocytes [32], lymphoblastoid cell lines [24], and fi-
broblasts [33]. In summary, the analysis of molecular
signaling pathways in lymphoblastoid cell lines from pa-
tients with autism may help to identify potential treatment
targets. More work is needed to assess if the molecular
defect identified here, increased expression and activity of
the PI3K catalytic subunit p110δ, could serve as a disease-
modifying therapeutic target in autism.
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Additional file 1: Figure S1a-c. Phospho-S6 and S6-specific ELISA results
of independent repeats (CTR(repeat)) of the control shown in Fig. 1 (CTR)
as well as one additional control cell line (CTR-2). No significant differences
were detected in phospho-S6 levels (a, one-way ANOVA, n = 5–6, F(2,14) =
0.07, p = 0.94), S6-levels (b, one-way ANOVA, n= 5–6, F(2,14) = 0.49, p = 0.62),
or pS6/S6 ratios (c, one-way ANOVA, n = 5–6, F(2,14) = 0.20, p = 0.82).
d Comparison of all healthy siblings of the tested SSC cell lines (Fig. 2)
shows that there was a significant difference (one-way ANOVA, n = 3–4,
F(36,109) = 1.7, p = 0.018). This difference was driven by sibling S37 who had
very low phospho-S6/S6 ratios, and when S37 was omitted, the p value was
0.18. Of note, this was an effect of the family S37, since S6 phosphorylation
of the proband S37 was very low, too, and there was no difference between
sibling S37 and the proband S37 (FDR-adjusted p = 0.919; Additional file 2:
Table S1b). Shown are means + SEM. (TIF 407 kb)
Additional file 2: Tables S1a and S1b. Complete list of p values for all
paired comparisons made in Figs. 1 and 2. a List of p values of Dunnett’s
post hoc analyses of each AGRE cell line compared to the healthy control.
Shown are values for post hoc analyses for total S6, phosphorylated S6, and
phospho-S6/S6 ratios. b List of false discovery rate-corrected p values of
pairwise comparisons of phospho-S6/S6 ratios of SSC cell lines. Highlighted
in yellow are comparisons with p < 0.05, which were considered significantly
different. (DOC 66 kb)
Additional file 3: Figure S2. Protein expression levels of PI3K catalytic
subunits p110α (a), p110β (b), and p110δ (c) are unchanged in cell lines S1
and S11 compared to their healthy siblings. Representative Western blots
are shown on the top, and densitometric quantifications of three to four
separate experiments are on the bottom (paired t tests, a, S1: n = 4, t(3) =
1.75, p = 0.178; S11: n = 3, t(2) = 0.60, p = 0.607; b, S1: n = 4, t(3) = 1.79, p =
0.171; S11: n = 4, t(3) = 2.09, p = 0.128; c, S1: n = 4, t(3) = 0.79, p = 0.487;
S11: n = 4, t(3) = 1.36, p = 0.266). Shown are means + SEM. (TIF 376 kb)
Additional file 4: Tables S2a and S2b. a, p values of Dunnett’s post
hoc analyses of p110δ protein expression analyses of the multiplex
family shown in Fig. 5b. b, p values of Dunnett’s post hoc analyses
of phospho-S6/S6 ratios measured by ELISA of the multiplex family
shown in Fig. 5c. All individual family members were compared to
the unaffected sister A4-S. (DOC 7 kb)
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